Inamura Kentaro, Amori Gulanbar, Yuasa Takeshi, Yamamoto Shinya, Yonese Junji, Ishikawa Yuichi
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Cancer Manag Res. 2019 Jul 25;11:7021-7030. doi: 10.2147/CMAR.S209205. eCollection 2019.
B7-H3 (CD276), an immune checkpoint molecule, regulates the tumor-immune microenvironment and controls the aggressiveness of various tumors. Although B7-H3 expression has been associated with the number of tumor-infiltrating FOXP3+ regulatory T cells, little information is available about this association in clear cell renal cell carcinoma (ccRCC).
Using 252 consecutive cases of ccRCC, we examined the association of B7-H3 expression in both the tumor cells and tumor vasculature with the number of tumor-infiltrating FOXP3+ cells and assessed whether the effects of B7-H3 expression on survival differ according to FOXP3+ cell number.
High B7-H3 expression was observed in the tumor cells and tumor vasculature in 15% and 54% of ccRCC cases, respectively. High FOXP3+ cell number was positively associated with B7-H3 expression in both the tumor cells (odds ratio [OR] =2.93; =0.0041) and tumor vasculature (OR=2.45; =0.0007). Tumor cell B7-H3 expression was associated with increased disease-specific mortality in high FOXP3+ cell number group (hazard ratio [HR] =2.98; =0.017), but not in low FOXP3+ group (=0.71). Tumor vasculature B7-H3 expression was also associated with increased disease-specific mortality in high FOXP3+ cell number group (HR=4.86; =0.0025), but not in low FOXP3+ group (=0.48).
We demonstrate that B7-H3 expression in both tumor cells and the tumor vasculature is positively associated with FOXP3+ cell number. Such expression is also associated with increased mortality in high FOXP3+ cell number group, but not in low FOXP3+ cell number group. These findings suggest that B7-H3-expressing ccRCCs may exert tumor-promoting immunity by interacting with FOXP3+ regulatory T cells in the tumor microenvironment.
免疫检查点分子B7-H3(CD276)可调节肿瘤免疫微环境并控制各种肿瘤的侵袭性。虽然B7-H3表达与肿瘤浸润性FOXP3 +调节性T细胞数量有关,但在透明细胞肾细胞癌(ccRCC)中,关于这种关联的信息却很少。
我们使用252例连续的ccRCC病例,研究肿瘤细胞和肿瘤血管中B7-H3表达与肿瘤浸润性FOXP3 +细胞数量的关联,并评估B7-H3表达对生存的影响是否因FOXP3 +细胞数量而异。
在ccRCC病例中,分别有15%和54%的肿瘤细胞和肿瘤血管中观察到高B7-H3表达。高FOXP3 +细胞数量与肿瘤细胞(优势比[OR]=2.93;P = 0.0041)和肿瘤血管(OR = 2.45;P = 0.0007)中的B7-H3表达均呈正相关。在高FOXP3 +细胞数量组中,肿瘤细胞B7-H3表达与疾病特异性死亡率增加相关(风险比[HR]=2.98;P = 0.017),而在低FOXP3 +组中则无相关性(P = 0.71)。肿瘤血管B7-H3表达在高FOXP3 +细胞数量组中也与疾病特异性死亡率增加相关(HR = 4.86;P = 0.0025),而在低FOXP3 +组中则无相关性(P = 0.48)。
我们证明肿瘤细胞和肿瘤血管中的B7-H3表达均与FOXP3 +细胞数量呈正相关。这种表达在高FOXP3 +细胞数量组中也与死亡率增加相关,但在低FOXP3 +细胞数量组中则无相关性。这些发现表明,表达B7-H3的ccRCC可能通过与肿瘤微环境中的FOXP3 +调节性T细胞相互作用发挥促肿瘤免疫作用。